Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection
- PMID: 37098552
- PMCID: PMC10127947
- DOI: 10.1186/s13020-023-00749-1
Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection
Abstract
Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the 'Diagnosis and Treatment Protocol for COVID-19 (Trial)' by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.
Keywords: Big brand traditional Chinese medicine; Respiratory tract infections; Secondary development of TCM; Shufeng Jiedu Capsule; Systematical research.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review.Drug Discov Ther. 2022 Jan 15;15(6):289-299. doi: 10.5582/ddt.2021.01099. Epub 2021 Dec 30. Drug Discov Ther. 2022. PMID: 34980761 Review.
-
Polysaccharides isolated from shufeng jiedu capsules by cross-flow ultrafiltration show anti-inflammatory effects on LPS-stimulated RAW264.7 cells and zebrafish inflammatory models.J Ethnopharmacol. 2025 May 28;348:119817. doi: 10.1016/j.jep.2025.119817. Epub 2025 Apr 17. J Ethnopharmacol. 2025. PMID: 40250639
-
Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.Biomed Pharmacother. 2020 Jan;121:109652. doi: 10.1016/j.biopha.2019.109652. Epub 2019 Nov 14. Biomed Pharmacother. 2020. PMID: 31734578
-
Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALI.J Ethnopharmacol. 2022 Nov 15;298:115661. doi: 10.1016/j.jep.2022.115661. Epub 2022 Aug 21. J Ethnopharmacol. 2022. PMID: 36002086 Free PMC article.
-
[Overview of systematic reviews of Shufeng Jiedu Capsules].Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):1103-1113. doi: 10.19540/j.cnki.cjcmm.20210712.501. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 35285211 Review. Chinese.
Cited by
-
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.Front Pharmacol. 2024 May 27;15:1383831. doi: 10.3389/fphar.2024.1383831. eCollection 2024. Front Pharmacol. 2024. PMID: 38863976 Free PMC article.
-
An advanced network pharmacology investigation of Shufeng Jiedu formula in the treatment for respiratory tract infection based on LC-MS, data mining, molecular docking, and molecular dynamic simulation.Brief Bioinform. 2025 Jul 2;26(4):bbaf353. doi: 10.1093/bib/bbaf353. Brief Bioinform. 2025. PMID: 40794954 Free PMC article.
-
Chinese Medicine Strategies for Influenza A: Research Progress and Prospects.Chin J Integr Med. 2025 Aug 11. doi: 10.1007/s11655-025-3941-7. Online ahead of print. Chin J Integr Med. 2025. PMID: 40788470 Review. No abstract available.
References
-
- Li YX. Clinical curative effect observation of Shufeng Jiedu capsule on wind-heat cold. Clin J Tradit Chin Med. 2015;27(05):674–675.
-
- Hu R, Wang LH, Zhang JJ, et al. Clinical observation of Shufeng Jiedu Capsule for treating acute pharyngitis. Drug Eval Res. 2014;37(05):460–462.
-
- Hu XY, Oliver T, Willcox M, et al. Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial. Pilot Feasibility Stud. 2022;8(1):262. doi: 10.1186/s40814-022-01224-8. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous